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ORIGINAL ARTICLE
Effectiveness of Positron Emission Tomography
for Predicting Chemotherapy Response
in Colorectal Cancer Liver Metastases
Evan S. Glazer, MD; Karen Beaty, PA-C; Eddie K. Abdalla, MD;
J. Nicolas Vauthey, MD; Steven A. Curley, MD
Hypothesis: Chemotherapeutic agents may be able to
convert unresectable colorectal hepatic metastasis to
resectable disease, therefore changing the surgical
options. The role of positron emission tomography
(PET) for patients undergoing chemotherapy remains
unclear. We hypothesize that recent chemotherapy
treatment could result in false-negative PET results.
Design: Case-control study evaluating PET findings.
Setting: The University of Texas M. D. Anderson Can-
cer Center.
Patients: From May 1, 2006, through August 31,
2008, data for 224 consecutive patients were entered
into a prospective database for evaluation of hepatic
metastasis of colorectal carcinoma. One hundred
thirty-eight patients underwent PET and conventional
imaging (a combination of computed tomography,
magnetic resonance imaging, and ultrasonography).
All had oncologically sound colorectal operations.
Interventions: Liver resection or ablation for colorec-
tal liver metastases.
Main Outcome Measures: To determine the accu-
racy of PET scans to detect residual viable colorectal can-
cer liver metastases after a significant response to sys-
temic chemotherapy.
Results: Patients with biopsy-proven disease under-
went hepatic resection (120 patients [87.0%]), radiofre-
quency ablation (2 [1.4%]), or resection with radiofre-
quency ablation (7 [5.1%]). Nine patients (6.5%) had
inoperable disease that was found intraoperatively.When
performed within 4 weeks of chemotherapy, PET had a
negative predictive value of 13.3% and a positive predic-
tive value of 94.3%. The sensitivity was 89.9%, the speci-
ficity was 22.2%, and the accuracy was 85.5%.
Conclusions: Positron emission tomography within 4
weeks of chemotherapy is not a useful test for evalua-
tion of colorectal hepaticmetastases. Thehigh rate of false-
negative results is likely due tometabolic inhibition caused
by chemotherapeutic drugs. We recommend that phy-
sicians not use PET in patients recently completing che-
motherapy; they should undergo the appropriate onco-
logic hepatic operation based on the high probability of
viable malignant disease.
Arch Surg. 2010;145(4):340-345
T HE ROLE OF SURGERY INcolorectal hepatic metasta-ses is undergoing a revolu-tion of sorts. For example,a few years ago an extrahe-
paticmetastasis effectively eliminated sur-
gical resection, but a combination of
chemotherapeutic options and surgical
techniqueshas expanded the indications for
resection and increased the population of
patients who may benefit.1,2 Neoadjuvant
chemotherapy has increased the resectabil-
ity rate by 11% to 37%.1 Unfortunately,
greater than80%ofpatients undergoinghe-
patic resectionwill have recurrences,mostly
within the first 2 years.2 Nonetheless, the
only hope for cure is resection, and prior
surgical dogma based on the number of le-
sions, size of the tumor-free resectionmar-
gin, and presence of resectable extrahe-
patic disease must be questioned.3-5 The
current standard approach to surgical plan-
ning is contrast-enhanced computed to-
mography (CT) or magnetic resonance
imaging (MRI) for specific tumor charac-
teristics or contraindications to CT.6 Sev-
eral series showed that focal extrahepatic
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disease, an isolated pulmonary lesion, can be safely re-
sected, with 5-year survival rates of 29% to 58%.7,8 In 1
series,7 17 of 30 patients required 3 or more resections.
Clearly, this is an extremely selected patient population.
As the opportunities to resect hepatic and focal
extrahepatic colorectal metastases continue to improve,
choosing the appropriate patient population becomes
imperative. Imaging modalities such as CT and MRI
provide detailed anatomic information regarding the
nature of the lesion but no functional information.
Transcutaneous ultrasonography is even less invasive
but often less accurate.9 Finally, positron emission
tomography (PET) using fluorine-18–labeled deoxyglu-
cose detects increased metabolic activity (uptake). This
can represent metastatic disease, new primary disease,
infectious causes, inflammation, or any increase in the
cellular use of glucose.
At present, the poor anatomic resolution of PET does
not allow for its isolated use to plan operations; how-
ever, it is often used in combination with CT and/orMRI
for diagnostic imaging.1,6,9 Exactly what PET adds to sur-
gical decision making remains unclear. A meta-
analysis9 found that PEThadhigher sensitivity rates (76%)
for detection of malignant lesions than did helical CT
(64%) orMRI (71%). That meta-analysis included 61 ar-
ticles from 1990 to 2003. The criterion standard applied
was pathologic tissue diagnosis. Chemotherapy changes
the activity of a malignant lesion,1,10,11 but exactly how
much is unclear. There appears to be a correlation be-
tween decreasing PETuptake and reduction in tumor bur-
den; however, hypometabolic lesionsmay still harbor vi-
ablemalignant cells.10,11 In addition, the authors reviewed
the temporal relationship between chemotherapy and
false-negative and false-positive results on PET. The false
response rate has been reported to be up to 20% if PET
is performed within 5 weeks of chemotherapy treat-
ment.10 Thus far, similar studies11 have had too few pa-
tients to reach a conclusive decision regarding the role
of PET in colorectal hepatic metastases.
Therefore, we reviewed our patient population for
the temporal relationship between PET results and
tissue-proven hepatic metastases from colorectal carci-
noma. The impetus for this research was finding viable
cancer in patients with clearly negative findings on
PET. We hypothesized that PET uptake levels were arti-
ficially decreased after chemotherapy. That is, lesions
that appeared to be nonmalignant were actually viable
malignant lesions.
METHODS
FromMay 1, 2006, through August 31, 2008, data for 224 con-
secutive patients were entered into a database for evaluation
of hepatic metastasis of colorectal carcinoma. All underwent
oncologically sound colon resections. One hundred thirty-
eight patients underwent PET and conventional imaging (a com-
bination of CT, MRI, and ultrasonography). The presumptive
diagnosis was hepatic metastatic disease. No patient had only
PET results, and all PET was performed in the latter half of the
chemotherapeutic protocol or within 4 weeks of terminating
chemotherapy. All patients had tissue-proven diagnoses of he-
patic metastases.
Patients underwent exploratory laparotomy to exclude the
presence of unresectable extrahepatic metastatic disease. Intra-
operative ultrasonography was used in all cases to detect the lo-
cation and size of hepatic tumors and to guide the decision to
proceed with an anatomic (hemihepatectomy or segmental re-
section)ornonanatomic (wedge) resection.Only9patients (6.5%)
received radiofrequency ablation as the therapeutic component
of their liver procedure after biopsy findings consistentwithmeta-
static disease.Where available, we reviewedwhich chemothera-
peutic regimen patients received before or during PET.
We used SPSS statistical software (version 11.04; SPSS Inc,
Chicago, Illinois) to analyze the data. Statistical significancewas
set at =.05. The institutional review board of our hospital ap-
proved this study.
RESULTS
Two hundred twenty-four patients met the initial crite-
ria. However, only 138 had at least 1 PET scan subse-
quent to chemotherapy and before liver intervention. The
average agewas 56 years; the population included 86men
(62.3%) and 52women (37.7%). Hepaticmetastaseswere
initially diagnosedusingPET in39patients (28.3%).Nine-
teen of these 39 (49%) underwent resection without ad-
ditional imaging; typically, they had a recent CT scan that
provided sufficient anatomic detail to proceed with a re-
section. One patient had a metastatic lesion with a nega-
tive finding on CT and a positive finding on PET. No pa-
tient had PET-positive and MRI-negative findings. In
addition, no further site of disease was seen on PET that
was not previously seen on CT, MRI, or ultrasonogra-
phy or during intraoperative assessment.
The primary diagnosis was mucinous colonic carci-
noma in 2 patients and adenocarcinoma in 136 patients.
At initial presentation for the primary colorectal lesion,
70 (50.7%) hadmetastatic disease. Before resection of the
primary tumor, 97 (70.3%) had no neoadjuvant therapy.
Twenty-two (15.9%) had chemoradiotherapy, whereas
19 (13.8%) received only chemotherapy as their neoad-
juvant therapy. Most patients underwent multimodality
imaging of their thorax and abdomen after their colo-
rectal surgery; 3.2% were diagnosed as having liver me-
tastases at the time of their primary colorectal proce-
dure, 4.0%with ultrasonography, 9.5%withMRI, 52.4%
with CT, and 31.0% with PET, as seen in the following
tabulation listing the initial methods of diagnosis.
Method No. (%) of Patientsa
Primary operation 4 (3.2)
MRI 12 (9.5)
CT 66 (52.4)
PET 39 (31.0)
Ultrasonography 5 (4.0)
aTwelve patients (8.7%) presented to our institution with multiple studies
or incomplete records showing liver metastases, and a single primary source
of diagnosis could not be determined, leaving 126 patients available for this
analysis. Because of rounding, percentages may not total 100.
Patients with biopsy-proven disease underwent
hepatic resection (120 patients [87.0%], radiofrequency
ablation [1.4%], or resection with radiofrequency abla-
tion [5.1%]. After chemotherapy delivered for 4 weeks
or less in advance of liver resection (Table 1), the
false-negative rate for hepatic metastasis of the PET was
86.7% (n=13) with a negative predictive value (NPV)
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of 13.3% (2 true-negative and 13 false-negative find-
ings). These patients underwent hepatic wedge resec-
tion and possible ablation based on CT or MRI findings
despite negative PET findings. The odds ratio for
predicting hepatic metastasis vs a benign cause was
2.55 (95% confidence interval [CI], 0.55-12.21
[P=.25]). As a test, PET yielded 116 true-positive, 13
false-negative, 7 false-positive, and 2 true-negative find-
ings (Table 2). The sensitivity rate for PET was 89.9%,
with a specificity rate of 22.2%. The positive predictive
value (PPV) was 94.3% (116 true-positive and 7 false-
positive findings). The accuracy was 85.5%, as seen in
the following tabulation.
Statistical Measure Percentage (95% CI)
Sensitivity 89.9 (83.3-94.5)
Specificity 22.2 (2.8-60.0)
PPV 94.3 (88.6-97.7)
NPV 13.3 (1.7-40.5)
Accuracy 85.5 (78.5-90.9)
Nine of 10 patients (90%) with poorly differenti-
ated colon adenocarcinoma metastases had positive
PET findings.
More than 85% of patients had a reduction of
greater than 25% in hepatic tumor burden after che-
motherapy according to multimodality imaging
results. Slightly less than half of the patients had a
reduction of greater than 50% in their metastasis, as
seen in the following tabulation.
Pathologically Confirmed
Radiologic Response
No. (%)
of Patientsa
Complete (90%) 3 (3.4)
Major (50% to 90%) 35 (40.2)
Minor (25% to 50%) 37 (42.5)
None (25%) 12 (13.8)
a Results are included only if comparisons are with actual previous
imaging studies (n=87). Previous studies were missing in 51 patients
(37.0%). Because of rounding, percentages may not total 100.
Of this very select group of patients, we report a 93.5%
survival rate at a median follow-up time of 15 months
(range, 1 week to 6 years). Median time to death after
the first 90 days (n=7) was 9.4 (range, 6.5-48.3)months.
There was a single perioperative death (at 1 week) and
another death during the first 90 days for a total 90-day
mortality rate of 1.4%.
COMMENT
The management of metastatic colorectal carcinoma is
evolving drastically. Often, PET is used as confirmation
of CT/MRI findings or for whole-body surveillance.
Within 4 weeks of chemotherapy, however, liver lesions
may or may not be adequately identified on CT/MRI,
and these are not reliably identified on PET (Figure 1
and Figure 2). Figure 1 clearly shows a primary colo-
rectal adenocarcinoma and liver metastasis in a man
aged 61 years. This CT-PET reconstruction demon-
strates the possible value of PET. Unfortunately, as we
report, this correlation or confirmation between CT and
PET is not uniform. The patient in Figure 2 underwent
Table 1. Chemotherapy Before Positron Emission
Tomographya
No. (%)
of Patients
FOLFOX plus bevacizumab 76 (60.3)
FOLFOX 24 (19.0)
FOLFOX plus cetuximab 5 (4.0)
Oxaliplatin, bevacizumab, and capecitabine 5 (4.0)
Fluorouracil 3 (2.4)
Other 13 (10.3)
Capecitabine 2 (1.6)
FOLFIRI plus bevacizumab 2 (1.6)
FOLFOX plus panitumumab 2 (1.6)
Fluorouracil and irinotecan hydrochloride 1 (0.8)
Capecitabine, irinotecan, and bevacizumab 1 (0.8)
FOLFIRI 1 (0.8)
FOLFOX plus bevacizumab and cetuximab 1 (0.8)
FOLFOX plus irinotecan 1 (0.8)
Irinotecan, cetuximab, and bevacizumab 1 (0.8)
Oxaliplatin, bevacizumab, and irinotecan 1 (0.8)
Abbreviations: FOLFIRI, leucovorin (folinic acid), fluorouracil, and
oxaliplatin; FOLFOX, leucovorin calcium (folinic acid), fluorouracil, and
oxaliplatin.
a Includes patients receiving chemotherapy for colorectal carcinoma after
colon resection with subsequent diagnosis of hepatic metastases (n=126);
12 patients (8.7%) were missing.
Table 2. Relationship Between Positron Emission
Tomography (PET) Results and Hepatic Lesionsa
PET Results
Hepatic Metastases,
No. of Patients
Positive Negative
Positive 116 7
Negative 13 2
a Includes tissue-proven results of PET after chemotherapy. Readings were
by experienced radiologists with expertise in abdominal cancer.
10.0
0.0
Figure 1. Hypermetabolic regions of the primary tumor (distal sigmoid
colorectal adenocarcinoma) and biopsy-proven hepatic metastatic disease
are denoted by arrows. Background (normal) metabolism is seen in other
parts of the gastrointestinal tract. The patient is a man aged 61 years. The
scale is given in standard uptake values.
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an oncologically sound partial colectomy with hepatic
recurrence 6 months after surgery. The PET portion of
the scan clearly yielded negative findings. However, this
patient had pathologically proven metastatic disease.
This is seen on the CT portion of the image (changes in
the gray scale rather than the intensity of red pseudo-
color) of Figure 2.
As we described, the sensitivity rate for PET in this
setting is relatively high at 89.9%, suggesting that the ra-
tio of true-positive to false-negative values is high. This
is true, but it is incomplete. Comparing false-negativewith
true-negative findings (the false-negative rate) yields a
slightly different picture: an 86.7% false-negative rate
(equivalent to stating a 13.3% NPV). That is, when the
PET finding is negative, it cannot be trusted (Figure 2).
The NPV depends on the population being analyzed,
which is where this unique situation develops.
The prevalence of early hepatic metastatic disease is
high (the median disease-free interval is 1 year after
colon resection),6 whereas PET findings will be positive
only for metabolic activity above baseline. The goal of
chemotherapy is to decrease malignant cell metabolic
activity, ideally, to zero and induce apoptosis/necrosis
and cell death. A priori, then, PET would not be
expected to yield useful information after an effective
chemotherapeutic regimen until malignant cells recov-
ered enough metabolic activity that is greater than the
surrounding tissues. Our results confirm this finding,
and they are in line with other evidence in the litera-
ture.9,10 Exactly how long to wait after chemotherapy
until PET becomes useful is unknown, but longer than
8 weeks seems reasonable.
Most of these patients undergo abdominal-pelvic CT
before initial colon resection, and comparing that scan
with postchemotherapeutic imaging may be a better
alternative. Changes in lesions (or any new lesions) are
then treated accordingly. If a lesion is worrisome on CT
or MRI within 4 to 6 weeks of finishing chemotherapy,
it should then be surgically removed regardless of the
PET results. In this study, the PPV was very high
(94.3%). Again, the PPV varies with the population
being studied, as described in other studies.1,6,9 The
prevalence of hepatic metastases is greater than 50%
during the first 5 years after diagnosis. On surveillance
imaging, a positive PET finding without CT findings
poses a diagnostic dilemma if the temporal relationship
to chemotherapy is short. Of the 7 false-positive find-
ings, PET was the modality of diagnosis in 3 (43%).
This suggests that 3 of the 138 operations (2.2%) would
have been prevented if PET had not been performed.
This rate is similar to those of other cost-benefit and
decision analyses.12 Another report13 suggests that up to
24% of patients with negative preoperative imaging
results show macroscopic disease at the time of opera-
tion at that same site.
Furthermore, there were only 10 patients with poorly
differentiated colon adenocarcinoma livermetastases.One
of these 10 had a negative PET finding. The PPV of 94.3%
and the small proportion of poorly differentiated le-
sions (10 of 138 [7.2%]) suggest that these results are
valid for nearly all patients regardless of the degree of dif-
ferentiation of their disease.
No survival benefit has been seen in the use of PET
by other groups.6,12 We had a median follow-up of 15
months with 93.5% of patients alive. This population is
obviously extremely selected but shows that, in a se-
lected population, clinically significant improvements can
bemade. Of those dying despite surgery, themedian time
to death was 9.4 months. The Surveillance, Epidemiol-
ogy, and End Results data14 show an 11% 5-year sur-
vival rate with distant disease. It is difficult to extrapo-
late howmany of our patients will be alive at 5 years, but
A
B
Figure 2. Detection of a metastatic liver lesion 6 months after resection of a
colorectal carcinoma. A, A biopsy-proven metastatic liver lesion is seen on
the computed tomography (CT) component of the CT–positron emission
tomography (PET) study (arrow). B, The lesion is not seen on either the PET
or the CT portion of a combined CT-PET study.
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it appears that this population benefits from surgical in-
tervention for their metastatic disease.
Finally, the distinction between radiologic and
pathologic responses is an important one. The current
technological age allows for unprecedented imaging
before surgical intervention. This, coupled with the
increasing evidence-based approaches to surgery, not
only allows but requires that we investigate surgical
decision making. Investigators at our own institution15
recently showed that pathologic response is an indepen-
dent predictor of survival in these patients. Although
imaging techniques are very valuable, functional studies
are not sufficiently accurate for surgical planning or
decision making. An interesting study would begin
serial PET scans at the time of initial primary colorectal
cancer diagnosis at colonoscopy. Although this would
be expensive, it would quantify the effects of multiple
therapies, the patient’s global health, and chemothera-
peutics on the functional status of these lesions. At
present, few of our patients undergo PET before receiv-
ing any treatment; therefore, the likelihood of a nega-
tive finding a priori is not known for this population.
However, if these findings were all positive, we would
still not recommend performing repeated PET after che-
motherapy. In addition, if these previously positive
findings on PET were negative after chemotherapy, this
would provide further support to not perform
follow-up PET.
At current practice, our algorithm is as follows: If che-
motherapy has not been given for 6 weeks or longer, we
recommend patients undergo CT-PET with reconstruc-
tions. If chemotherapy is ongoing or has been adminis-
tered within the past 6 weeks, we recommendCT orMRI
only, obtaining whichever type of scan that the patient
has undergone previously to allow direct comparison.
Prior comparisons are one of the most important tools
in determining the likelihood of a malignant lesion and
response to therapy. If there are any suspected malig-
nant lesions or changes, we recommend resection if pos-
sible, ablation if not.
CONCLUSIONS
A unique situation arises in the use of PET with hepatic
metastases of colorectal carcinoma during or soon after
chemotherapy. Routine surveillance with CT or MRI
often yields findings for metastatic disease, but clinical
confirmation is desired. Unfortunately, although the
accuracy rate is 85.5%, this test should not be used in
surgical decision making. A positive test result does not
alter the surgical plan, whereas a negative test result
should not be trusted. This is a slightly unusual high-
prevalence metastatic disease with a reasonably good
test (PET). Owing to the nature of the metastatic dis-
ease and the poor prognosis, aggressive surgical inter-
vention is warranted. Positron emission tomography
allows for confirmation, but it does not and perhaps
should not change the surgical recommendations to the
patients and their families within 4 to 6 weeks of receiv-
ing chemotherapy because the NPV is too low. A ran-
domized, controlled trial would clearly answer the
questions, but the ethics involved in not subjecting
worrisome lesions to biopsy after nonfunctional studies
(ie, CT or MRI) are prohibitive. More aggressive percu-
taneous biopsy might be an appropriate compromise in
a highly selective situation, but even in the presence of
isolated extrahepatic disease, definitive surgical inter-
vention yields the best chance for survival.
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INVITED CRITIQUE
Positron Emission Tomography
for Colorectal Cancer Liver Metastases
Where’s the Value?
A dvances in chemotherapy during the past de-cade have created an evolving paradigm for treat-ing patients with liver metastases from colorec-
tal cancer, particularly in increasing the resectability rate.1
Themanagement of disease in these patients relies heavily
on imaging with CT and MRI. Positron emission tomog-
raphy is frequently used. In the preceding article, Glazer
et al retrospectively analyzed the utility of PET in theman-
agement of disease in these patients. This article is impor-
tant because it highlights the limitations of PET in pre-
dicting response to chemotherapy. Figures 1 and 2 nicely
demonstrate the problem. Despite a negative PET find-
ing, viable tumor is likely to be present. The NPV of PET
performed within 4 weeks of chemotherapy was 13.3%.
As the authors postulate, chemotherapy interrupts the
metabolism of tumor cells to induce apoptosis and cell
death. Some cellsmay survivewithmetabolic activity simi-
lar to that of the surrounding tissue and thus cannot be
detected on PET 4 weeks after chemotherapy. The opti-
mal timing for performing PET after chemotherapy is not
known, but it is likely that there will be fewer false-
negative scans after a longer interval following comple-
tion of chemotherapy.
In this study, only a few patients had PET before any
therapy, so the metabolic activity of the primary tumor
and its ability to be visualized on PET is unknown. Also,
although the PPV of PETwas 94.3% in this study, a posi-
tive finding did not change the surgical plans.
Positron emission tomography is expensive and should
be used only if the results will alter management.
I agree with the authors that surgical decisions should
not be based on the results of PET without further inves-
tigation. The algorithm that they offer is reasonable and
relies on a comparison of current with prior CT or MRI
findings. Themovie is usuallymore useful than the snap-
shot, in particular to identify change. Despite the au-
thors’ findings in this study, their algorithm recommends
PET be performed if more than 6weeks have lapsed since
chemotherapy.Why shouldwe trust a negative PET find-
ing 6 weeks after chemotherapy? I would hope that the
authors and others will continue to evaluate this in well-
managed trials. Until that time, surgical decisions in pa-
tients with colorectal liver metastases should be based on
careful clinical evaluation and serial CT or MRI studies.
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